F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin, vol.68, pp.394-424, 2018.

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al., Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States, Cancer Res, vol.74, pp.2913-2921, 2014.

J. Kleeff, M. Korc, and M. Apte, Pancreatic cancer, Nat. Rev. Dis. Primers, vol.2, 2016.

M. Aslan, R. Shahbazi, K. Ulubayram, and B. Ozpolat, Targeted Therapies for Pancreatic Cancer and Hurdles Ahead, Anticancer Res, vol.38, pp.6591-6606, 2018.

D. P. Ryan, T. S. Hong, N. Bardeesy, . Pancreatic, and . Adenocarcinoma, N. Engl. J. Med, vol.371, pp.1039-1049, 2014.

R. Hassan, A. Thomas, C. Alewine, D. T. Le, E. M. Jaffee et al., Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, J. Clin. Oncol, vol.34, pp.4171-4179, 2016.

F. Nichetti, A. Marra, and F. Corti, The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review, Targ Oncol, vol.13, pp.333-351, 2018.

E. Sharon, J. Zhang, K. Hollevoet, S. M. Steinberg, I. Pastan et al., Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers, Clin. Chem. Lab. Med, vol.50, pp.721-725, 2012.

C. Montemagno, S. Bacot, M. Ahmadi, B. Kerfelec, D. Baty et al., Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer, J. Nucl. Med, vol.59, pp.1056-1062, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02115385

A. Adamska, A. Domenichini, and M. Falasca, Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies, Int. J. Mol. Sci, vol.18, 1338.

T. K. Bera and I. Pastan, Mesothelin Is Not Required for Normal Mouse Development or Reproduction, Mol. Cell. Boil, vol.20, pp.2902-2906, 2000.

A. Morello, M. Sadelain, and P. S. Adusumilli, Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors, Cancer Discov, vol.6, pp.133-146, 2016.

Z. Tang, C. Li, B. Kang, G. Gao, C. Li et al., GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Res, vol.45, pp.98-102, 2017.

P. Argani, C. Iacobuzio-donahue, B. Ryu, C. Rosty, M. Goggins et al., Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression

, Clin. Cancer Res, vol.7, pp.3862-3868, 2001.

L. Zhu, Y. Liu, and G. Chen, Diagnostic value of mesothelinin pancreatic cancer: A meta-analysis, Int. J. Clin. Exp. Med, vol.7, pp.4000-4007, 2014.

F. M. Johnston, M. C. Tan, B. R. Tan, M. R. Porembka, E. M. Brunt et al., Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer, Clin. Cancer Res, vol.15, pp.6511-6518, 2009.

Z. W. Kendrick, M. A. Firpo, R. C. Repko, C. L. Scaife, D. G. Adler et al., Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer, HPB, vol.16, pp.670-676, 2014.

E. J. Ter-weele, A. G. Terwisscha-van-scheltinga, and J. G. Kosterink, Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts, Oncotarget, vol.6, pp.42081-42090, 2015.

H. Yakushiji, K. Kobayashi, F. Takenaka, Y. Kishi, M. Shinohara et al., Novel single-chain variant of antibody against mesothelin established by phage library, Cancer Sci, vol.110, pp.2722-2733, 2019.

K. Kobayashi, T. Sasaki, F. Takenaka, H. Yakushiji, Y. Fujii et al., A Novel PET Imaging Using 64Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells, J. Immunol. Res, pp.1-15, 2015.

, The Cancer Genome Atlas, 2019.

B. Györffy, A. Lanczky, and A. C. Eklund, An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients, Breast Cancer Res. Treat, vol.123, pp.725-731, 2010.

B. Gy?rffy, A. Lánczky, and Z. Szállási, Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients, Endocr. Related Cancer, vol.19, pp.197-208, 2012.

A. M. Szász, A. Lánczky, Á. Nagy, S. Förster, K. Hark et al., Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients, Oncotarget, vol.7, pp.49322-49333, 2016.

, The Genomics of Drug Sensitivity in Cancer (GDSC), 2019.